LTRN at a glance
The past year
Chart−91.2% $0.28, close Nov 19
- From the highest close
- −93.2%
- Vs the 200-day average
- −87.5%
Short interest
History924,479 shares
- Of shares outstanding
- 5.82%
- Since the last report
- +137.9%
- Days to cover
- 2.7 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 14 – Nov 20
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
LTRN price history
Loading recent earnings…
Investment thesis
What must happen next
Lantern’s AI-led oncology model must keep development spending materially leaner than a conventional biotech path while still advancing candidates; otherwise the promised cost-and-speed advantage is not economically real.HoldingMateriality: High
GAAP annual operating cash flow was -$15.7 million in FY2025 versus -$17.8 million in FY2024, showing cash burn declined year over year. If the platform truly lowers the cost of oncology development, each dollar of capital buys more shots on goal; if not, Lantern is just another cash-burning microcap biotech.
Watch: Clinical-trial execution, CRO, regulatory, or manufacturing requirements rise faster than the platform can offset as programs move deeper into human studies.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was -$15.7 million in FY2025 versus -$17.8 million in FY2024, showing cash burn declined year.
Open source ↗Lantern’s ability to capture value from its pipeline depends on securing capital or partnerships before liquidity dictates program delays, cuts, or highly dilutive equity issuance.WeakeningMateriality: High
Cash and cash equivalents were $4.4 million at FY2025 year-end, down from $7.5 million at FY2024 year-end and $21.9 million at FY2023 year-end. Financing terms will determine whether clinical upside accrues to current shareholders or is transferred to new investors and partners.
Watch: Lantern is unable to raise equity on acceptable terms before additional clinical milestones.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash and cash equivalents were $4.4 million at FY2025 year-end, down from $7.5 million at FY2024 year-end and $21.9 million.
Open source ↗The operating model relies on a very small internal team using the AI platform and outsourced capabilities; if advancing the pipeline requires a conventional large biotech organization, Lantern loses a central economic rationale.StrengtheningMateriality: Medium
Lantern reported 16 employees as of the 2026 filing date. A lean model preserves option value and reduces dilution; a forced buildout would raise fixed costs before any product revenue exists.
Watch: Clinical, regulatory, biomarker, manufacturing, or quality-control demands require a major internal hiring ramp.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Lantern reported 16 employees as of the 2026 filing date.
Open source ↗Lantern needs clinical or partnering validation to replenish enterprise value before cumulative losses shrink the asset base further.WeakeningMateriality: Medium
Total assets fell to $11.0 million at FY2025 year-end from $25.6 million at FY2024 year-end and $43.6 million at FY2023 year-end. Without validation, the company’s balance sheet erodes while the market has little tangible basis to capitalize the pipeline.
Watch: Oncology candidates fail to produce human efficacy or safety data strong enough to attract investors, acquirers, or licensing partners.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Total assets fell to $11.0 million at FY2025 year-end from $25.6 million at FY2024 year-end and $43.6 million at FY2023.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Lantern’s AI-led oncology model must keep development spending materially leaner than a conventional biotech path while still advancing candidates; otherwise the promised cost-and-speed advantage is not economically real. If the platform truly lowers the cost of oncology development, each dollar of capital buys more shots on goal; if not, Lantern is just another cash-burning microcap biotech.
Lantern’s ability to capture value from its pipeline depends on securing capital or partnerships before liquidity dictates program delays, cuts, or highly dilutive equity issuance. Financing terms will determine whether clinical upside accrues to current shareholders or is transferred to new investors and partners.
The operating model relies on a very small internal team using the AI platform and outsourced capabilities; if advancing the pipeline requires a conventional large biotech organization, Lantern loses a central economic rationale. A lean model preserves option value and reduces dilution; a forced buildout would raise fixed costs before any product revenue exists.
Lantern needs clinical or partnering validation to replenish enterprise value before cumulative losses shrink the asset base further. Without validation, the company’s balance sheet erodes while the market has little tangible basis to capitalize the pipeline.
All standing thesis claims
Original report summary
Lantern Pharma is a binary, financing-sensitive bet that its AI-driven oncology platform can produce partner-grade clinical evidence before cash burn forces highly dilutive capital.
Bull case and bear case
Bull case and bear case for Lantern Pharma
Where the evidence on Lantern Pharma disagrees: Mixed on the latest evidence (Nov 8, 2026). Of its 4 thesis points, 1 strengthening, 1 holding and 2 weakening.
Bull case: what the evidence supports
Lantern’s AI-led oncology model must keep development spending materially leaner than a conventional biotech path while still advancing candidates; otherwise the promised cost-and-speed advantage is not economically real.
The operating model relies on a very small internal team using the AI platform and outsourced capabilities; if advancing the pipeline requires a conventional large biotech organization, Lantern loses a central economic rationale.
Bear case: what the evidence questions
Lantern’s ability to capture value from its pipeline depends on securing capital or partnerships before liquidity dictates program delays, cuts, or highly dilutive equity issuance.
Lantern needs clinical or partnering validation to replenish enterprise value before cumulative losses shrink the asset base further.
Thesis-Break Engine
What has broken in Lantern Pharma’s thesis
Each break OptimistFi flagged on Lantern Pharma, dated — with what has historically followed the same kind of break across the market, not a forecast for Lantern Pharma.
- Late SEC filingcondition set before this filing
Across all companies, this kind of break has happened 4,811 times before. Those stocks trailed comparable companies by a median of 12% over the next six months, and 52% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedDelisting notice or listing-rule failure.
Lantern Pharma filed an SEC 8-K on 2026-10-01: Delisting notice or listing-rule failure. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Lantern Pharma filed an SEC 8-K on 2026-09-30: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Lantern Pharma filed an SEC 8-K on 2026-09-24: Regulation FD disclosure. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Clinical-trial execution, CRO, regulatory, or manufacturing requirements rise faster than the platform can offset as programs move deeper into human studies.
- Lantern is unable to raise equity on acceptable terms before additional clinical milestones.
- Clinical, regulatory, biomarker, manufacturing, or quality-control demands require a major internal hiring ramp.
- Oncology candidates fail to produce human efficacy or safety data strong enough to attract investors, acquirers, or licensing partners.
LTRN news
Loading headlines…
Financial statements
LTRN income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
LTRN: quick answers
- When does Lantern Pharma (LTRN) report earnings next?
- Lantern Pharma's next results are projected for February 17, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 18, 2026. Earnings calendar
- What is LTRN's short interest?
- As of October 30, 2026, 924,479 LTRN shares were sold short, 5.82% of its shares outstanding, up 137.9% from the count before. At the stock's average daily volume that is 2.7 days to cover. FINRA publishes the count twice a month. LTRN short interest history

